Reward-based technology to improve opioid use disorder treatment initiation after an ED visit

基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动

基本信息

  • 批准号:
    10337501
  • 负责人:
  • 金额:
    $ 49.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-30 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Millions of people in the US misuse opioids each year, leading to thousands of deaths and costing billions of dollars in total economic burden. Medication assisted treatment (MAT) for opioid use disorder (OUD) is highly efficacious, but only a fraction of OUD persons access MAT, and treatment non-adherence is common and associated with poor outcomes. This STTR Fast Track proposal is designed to increase rates of Suboxone (buprenorphine/naloxone) treatment initiation and adherence among OUD patients recruited from emergency and inpatient acute care. To accomplish these aims, the project will enhance the Opioid Addiction Recovery Support (OARS), an existing Q2i company technology, with a new evidence-based reward, contingency management (CM) function. CM interventions systematically reward (reinforce) specific behaviors like treatment initiation and adherence with therapy attendance and drug-free urine tests, and are highly efficacious. An OARS solution enhanced with a CM component (OARS+CM) that allows for the automatic calculation, delivery, and redemption of rewards contingent on objective evidence of treatment behaviors may be key to improving Suboxone initiation and adherence. In Phase 1 of this proposal, the existing OARS clinician portal and patient mobile application will be modified to accommodate entry into the software system from an acute care setting and to automatically manage and deliver rewards to create OARS+CM using patient-centered design principles. Usability sessions with OUD patients and other key stakeholders will inform design. Primary usability outcomes will be examined and the program iteratively updated. On meeting milestones, there will be proof-of-concept pilot of usability, acceptability, and effects on initial behavior targets with approximately 20 patients and at least 4 providers. On meeting milestones, a RCT will follow, in which acute care OUD patients appropriate for outpatient Suboxone (N = 150) are recruited and allocated to one of three study conditions: 1) treatment as usual (TAU), comprised of screening, brief intervention, and referral to treatment by a trained clinician, 2) OARS, and 3) OARS+CM. The active intervention window for the two intervention groups will be 12 weeks. Patients will be onboarded prior to discharge from acute care. In the outpatient Suboxone setting, data on treatment adherence and opioid use will be captured from clinical records for six months. Telephone follow-up assessments and vital statics registry reviews will be at month 1, month 3 (end-of-study intervention period), and month 6. Primary Suboxone treatment initiation outcomes will be scheduling and completing the Suboxone intake. Primary Suboxone treatment outcomes will be sustained abstinence at Month 6 and longest duration of abstinence. Analysis will examine data on cost avoidance and cost savings through reduced acute care visits between study conditions.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edwin D Boudreaux其他文献

Edwin D Boudreaux的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edwin D Boudreaux', 18)}}的其他基金

Signature Research Project
签名研究项目
  • 批准号:
    10577120
  • 财政年份:
    2023
  • 资助金额:
    $ 49.9万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10577118
  • 财政年份:
    2023
  • 资助金额:
    $ 49.9万
  • 项目类别:
The Center for Accelerating Practices to End Suicide through Technology Translation (CAPES)
通过技术转化加速结束自杀实践中心 (CAPES)
  • 批准号:
    10577117
  • 财政年份:
    2023
  • 资助金额:
    $ 49.9万
  • 项目类别:
CDR Administrative Supplement for COVID-19 Impacted NIMH Research
针对受新冠肺炎 (COVID-19) 影响的 NIMH 研究的 CDR 行政补充
  • 批准号:
    10617502
  • 财政年份:
    2022
  • 资助金额:
    $ 49.9万
  • 项目类别:
Telehealth to Improve Prevention of Suicide (TIPS) in EDs
远程医疗可改善急诊科的自杀预防 (TIPS)
  • 批准号:
    10322028
  • 财政年份:
    2021
  • 资助金额:
    $ 49.9万
  • 项目类别:
Telehealth to Improve Prevention of Suicide (TIPS) in EDs
远程医疗可改善急诊科的自杀预防 (TIPS)
  • 批准号:
    10532210
  • 财政年份:
    2021
  • 资助金额:
    $ 49.9万
  • 项目类别:
Reward-based technology to improve opioid use disorder treatment initiation after an ED visit
基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动
  • 批准号:
    10414138
  • 财政年份:
    2019
  • 资助金额:
    $ 49.9万
  • 项目类别:
Computerized Adaptive Suicidal Risk Stratification and Prediction
计算机化自适应自杀风险分层和预测
  • 批准号:
    10254382
  • 财政年份:
    2019
  • 资助金额:
    $ 49.9万
  • 项目类别:
Reward-based technology to improve opioid use disorder treatment initiation after an ED visit
基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动
  • 批准号:
    10794875
  • 财政年份:
    2019
  • 资助金额:
    $ 49.9万
  • 项目类别:
Deriving a Clinical Decision Rule for Suicide Risk in the Emergency Department Setting
得出急诊科自杀风险的临床决策规则
  • 批准号:
    10299606
  • 财政年份:
    2019
  • 资助金额:
    $ 49.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了